Mer­ck-part­nered biotech hands Roche its half-life ex­ten­sion tech as it piv­ots to im­muno-on­col­o­gy

It seems few can re­sist the rev­enue that can await a can­cer treat­ment.

Af­ter over a decade ex­tend­ing the half-life of med­i­cines for J&J, Genen­tech and oth­er large play­ers, Amu­nix is piv­ot­ing to de­vel­op el­e­ments of its plat­form in­to two ap­proach­es to im­muno-on­col­o­gy, one of which is an off-the-shelf al­ter­na­tive to CAR–T treat­ments. And they’re li­cens­ing a por­tion of the old­er tech­nol­o­gy to Roche for $40 mil­lion and $1.5 bil­lion in po­ten­tial mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.